| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-174SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-306SS | |||
| Azide and BSA Free | NBP2-80586 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44513 | |||
| Azide and BSA Free | NBP2-34569-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24749SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-174SS | |||
| Azide and BSA Free | NBP2-80897 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-71648SS | |||
| Azide and BSA Free | NBP2-80858 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-88113SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB500-181SS | |||
![Western Blot: NuMA Antibody [NB500-174] - Analysis of NuMA expression in Cos7 whole cell lysate.](http://images.novusbio.com/fullsize/NuMA-Antibody-Western-Blot-NB500-174-img0001.jpg "Western Blot: NuMA Antibody [NB500-174] - Analysis of NuMA expression in Cos7 whole cell lysate.")
![Immunocytochemistry/Immunofluorescence: NuMA Antibody [NB500-174] - Human HeLa cells fixed with 3.5% formaldehyde and stained with NB500-174 at 1:1000. The staining pattern shows the typical pattern for NuMA in the cell nucleus during interphase and on spindles during mitosis.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunocytochemistry-Immunofluorescence-NB500-174-img0003.jpg)
![Immunohistochemistry-Paraffin: NuMA Antibody [NB500-174] - Analysis of FFPE tissue section of human placenta using rabbit polyclonal NuMA antibody (NB500-174) at 5 ug/mL. Strong nuclear with moderate cytoplasmic immuno-reactivity of NuMA was observed in syncytiotrophoblast, cytiotrophoblasts, Hofbauer cells and the endothelial cells of chorionic villi capillaries. 10X Magnification.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunohistochemistry-Paraffin-NB500-174-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: NuMA Antibody [NB500-174] - NuMA antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunocytochemistry-Immunofluorescence-NB500-174-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: NuMA Antibody [NB500-174] - NuMA antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunocytochemistry-Immunofluorescence-NB500-174-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: NuMA Antibody [NB500-174] - Dynactin and NuMA display specific, steady-state binding at mitotic minus-ends. See also Figure 1-figure supplement 1 and Videos 1-3. Representative immunofluorescence image showing co-localization of NuMA (green) and p150 (dynactin subunit; cyan) at microtubule minus-ends in mitotic PtK2 cells (post-NEB) fixed after washout of 5 uM nocodazole. Scale bar, 10 um. Inset: zoom of white box, with 1 um scale bar. Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/29328), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunocytochemistry-Immunofluorescence-NB500-174-img0024.jpg)
![Immunohistochemistry-Paraffin: NuMA Antibody [NB500-174] - Analysis of FFPE tissue section of human normal breast using rabbit polyclonal NuMA antibody (NB500-174) at 5 ug/mL. The breast ductal/acinar epithelial cells, the myoepithelial cells and some cells in the surrounding connective tissue depicted a strong nuclear along with moderate cytoplasmic immuno-positivity for NuMA protein. The intra-lobular and the surrounding connective tissue also developed weak/potentially non-specific staining. 10X Magnification.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunohistochemistry-Paraffin-NB500-174-img0007.jpg)
![Immunohistochemistry-Paraffin: NuMA Antibody [NB500-174] - Analysis of FFPE tissue section of human normal spleen using rabbit polyclonal NuMA antibody (NB500-174) at 5 ug/mL. Most of the cells developed a strong nuclear along with moderate cytoplasmic immuno-positivity for NuMA protein. 10X Magnification.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunohistochemistry-Paraffin-NB500-174-img0008.jpg)
![Immunohistochemistry-Paraffin: NuMA Antibody [NB500-174] - Analysis of FFPE tissue section of human normal skin using rabbit polyclonal NuMA antibody (NB500-174) at 5 ug/mL. Almost all the cells in the epidermal layer and the cells in the connective tissue of dermal layer depicted very strong nuclear along with moderate cytoplasmic immuno-positivity for NuMA protein. 10X Magnification.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunohistochemistry-Paraffin-NB500-174-img0009.jpg)
![Immunohistochemistry-Paraffin: NuMA Antibody [NB500-174] - Analysis of FFPE tissue section of human normal brain using rabbit polyclonal NuMA antibody (NB500-174) at 5 ug/mL. The cells in the brain tissue depicted strong specific nuclear along with weak cytoplasmic immuno-positivity for NuMA protein. 10X Magnification.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunohistochemistry-Paraffin-NB500-174-img0010.jpg)
![Immunohistochemistry-Paraffin: NuMA Antibody [NB500-174] - Analysis of FFPE tissue section of human normal kidney using rabbit polyclonal NuMA antibody (NB500-174) at 5 ug/mL. The cells of various tubules/ducts and Bowman's capsule in the renal tissue depicted strong nuclear along with relatively weak cytoplasmic immuno-positivity for NuMA protein. 10X Magnification.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunohistochemistry-Paraffin-NB500-174-img0011.jpg)
![Immunohistochemistry-Paraffin: NuMA Antibody [NB500-174] - Analysis of FFPE tissue section of human normal prostate using rabbit polyclonal NuMA antibody (NB500-174) at 5 ug/mL. The prostatic alveolar glandular epithelium as well as the surrounding fibromuscular stroma cells showed a strong nuclear immuno-reactivity for NuMA protein. Almost all the cells developed some cytoplasmic staining also. 10X Magnification.](http://images.novusbio.com/fullsize/NuMA-Antibody-Immunohistochemistry-Paraffin-NB500-174-img0012.jpg)
![Simple Western: NuMA Antibody [NB500-174] - Image shows a specific band for NuMA in 0.2 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 66-440 kDa separation system.](http://images.novusbio.com/fullsize/NuMA-Antibody-Simple-Western-NB500-174-img0023.jpg)
![Immunohistochemistry: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - ATM [p Ser1981] antibody (10H11.E12) [NB100-306] was tested in mouse spleen using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Immunohistochemistry-NB100-306-img0005.jpg "Immunohistochemistry: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - ATM [p Ser1981] antibody (10H11.E12) [NB100-306] was tested in mouse spleen using DAB with hematoxylin counterstain.")
![Western Blot: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - Analysis of ATM-kinase, using ATM [p Ser1981] antibody (10H11.E12) [NB100-306]. Sample: Irradiated or peroxidated human fibroblasts. Observed molecular weight 370 kDa. Theoretical molecular weight 351 kDa.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Western-Blot-NB100-306-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - Human lymphoblastoid cells stained with ATM [p Ser1981] Antibody (10H11.E12). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Immunocytochemistry-Immunofluorescence-NB100-306-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - MCELNs decreased the DNA damage of H9C2 cells after radiation. Western blot images of p-ATM (NB100-306) and ATM (NB100-309) in H9C2 cells after 48 h of culture with indicated treatment. IR (-/+): 0/16 Gy X-ray; MCELNs (-/+): 0/10 ug/mL. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35509278/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nb100-306_mouse-monoclonal-atm-p-ser1981-antibody-10h11-e12-2552023151493.jpg)
![Western Blot: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Western blot shows lysates of Ramos human Burkitt's lymphoma parental cell line and B7-2 knockout (KO) Ramos cell line. PVDF membrane was probed with 1.0 ug/mL of Mouse Anti-Human B7-2 Monoclonal Antibody (Catalog # NBP2-25208) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for B7-2 at approximately 90 kDa (as indicated) in the parental Ramos cell line, but is not detectable in the knockout Ramos cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Knockout-Validated-NBP2-25208-img0005.jpg "<b>Genetic Strategies Validation. </b>Western Blot: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Western blot shows lysates of Ramos human Burkitt's lymphoma parental cell line and B7-2 knockout (KO) Ramos cell line. PVDF membrane was probed with 1.0 ug/mL of Mouse Anti-Human B7-2 Monoclonal Antibody (Catalog # NBP2-25208) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for B7-2 at approximately 90 kDa (as indicated) in the parental Ramos cell line, but is not detectable in the knockout Ramos cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Macrophage polarization states. Distribution and proportion of CD86+ macrophages (brown) were identified using IHC procedures. Intensity for the color response to antibodies was visible in lung tissues from all groups. Population proportions for the stained cells as shown by red arrows were calculated as a fold change of the control. (d). The results were expressed as Mean +/- SD (n = 3). **: a p-value of < 0.01 vs NS, OVA/BUD and OVA/PCI except the number of CD86+ cells in OVA/PCI group. #: P < 0.05 vs NS and ##; P < 0.01 vs either NS or OVA/BUD group. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-1322-5) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-NBP2-25208-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Immunofluorescence staining of PFA-fixed Ramos cells using followed by goat anti-Mouse IgG conjugated to CF488 (green). Nuclei are stained with Red Dot.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunocytochemistry-Immunofluorescence-NBP2-25208-img0006.jpg)
![Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Effects of 20(S)-Rg3 on macrophage polarization in atherosclerotic lesions of diabetic ApoE-/- mice. Co-immunofluorescence staining for macrophage (anti-Moma-2 antibody, green), M1 marker CD86 (red) and DAPI (blue) (n = 5, respectively). Scale bar: 20 um. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/articles/10.3389/fphar.2018.00464/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-NBP2-25208-img0010.jpg)
![Flow Cytometry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Flow Cytometric Analysis of PFA-fixed Ramos cells. B7-2/CD86 Antibody (BU63) followed by goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Flow-Cytometry-NBP2-25208-img0008.jpg)
![Immunohistochemistry-Paraffin: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Formalin-fixed, paraffin-embedded esophagus tumor tissue stained with CD86 antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen. Note strong staining of differentiated squamous cells. TMA was used for this test.](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Immunohistochemistry-Paraffin-NBP2-25208-img0004.jpg)
![Flow Cytometry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Flow Cytometric Analysis of human PBMCs using B7-2/CD86 Antibody (BU63); Goat anti-Mouse IgG-CF488 (red); Isotype Control (green).](http://images.novusbio.com/fullsize/B7-2-CD86-Antibody-BU63-Flow-Cytometry-NBP2-25208-img0007.jpg)
![Immunohistochemistry: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Macrophage polarization states. Distribution & proportion of CD68+ (a), CD86+ (c) & CD163+ (e) macrophages (brown) were identified using IHC procedures. Intensity for the color response to antibodies was visible in lung tissues from all groups. Population proportions for the stained cells as shown by red arrows were calculated as a fold change of the control. (b, d, f). The results were expressed as Mean ± SD (n = 3). **: a p-value of < 0.01 vs NS, OVA/BUD & OVA/PCI except the number of CD86+ cells in OVA/PCI group. #: P < 0.05 vs NS & ##; P < 0.01 vs either NS or OVA/BUD group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32111211), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25208_mouse-monoclonal-b7-2-cd86-antibody-bu63-imgenex-img-6882a-25ug-31020241534324.jpg)
![Immunocytochemistry/ Immunofluorescence: B7-2/CD86 Antibody (BU63) [NBP2-25208] - Effects of 20(S)-Rg3 on macrophage polarization in atherosclerotic lesions of diabetic ApoE–/– mice. (A,B) Co-immunofluorescence staining of the aortic root for macrophage (anti-Moma-2 antibody, green) & M1 marker iNos (red), & a bar graph summarizing the results (n = 5, respectively). (C,D) Co-immunofluorescence staining for macrophage (anti-Moma-2 antibody, green) & M1 marker CD86 (red), & a bar graph summarizing the results (n = 5, respectively). Scale bar: 20 μm. Data are mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29867472), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-25208_mouse-monoclonal-b7-2-cd86-antibody-bu63-imgenex-img-6882a-25ug-31020241535650.jpg)
![Immunohistochemistry: KLF4 Antibody [NBP2-24749] - DAB IHC staining. Representative 3,3-diaminobenzidine immunohistochemical-stained images showing protein expression of induced-pluripotent stem cell marker KLF4 (J-L, brown) in normal colon (J), low-grade (K) and high-grade (L) colon adenocarcinoma tissue samples. Nuclei were counter-stained with hematoxylin (A-O, blue). Original magnification: 400x. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0221963) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-NBP2-24749-img0006.jpg "Immunohistochemistry: KLF4 Antibody [NBP2-24749] - DAB IHC staining. Representative 3,3-diaminobenzidine immunohistochemical-stained images showing protein expression of induced-pluripotent stem cell marker KLF4 (J-L, brown) in normal colon (J), low-grade (K) and high-grade (L) colon adenocarcinoma tissue samples. Nuclei were counter-stained with hematoxylin (A-O, blue). Original magnification: 400x. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0221963) licensed under a CC-BY license.")
![Western Blot: KLF4 Antibody [NBP2-24749] - Total protein from Human PC3, Hek293 and Mouse Neuro2A cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-KLF4 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/KLF4-Antibody-Western-Blot-NBP2-24749-img0005.jpg)
![Immunohistochemistry: KLF4 Antibody [NBP2-24749] - IF IHC staining. Representative immunofluorescence immunohistochemical-stained images showing protein expression of induced-pluripotent stem cell markers OCT4 (A-C, green), KLF4 (A-C, red) in normal colon (A), low-grade (B) and high-grade (C) colon adenocarcinoma tissue samples. Cell nuclei were counter-stained with 4', 6'-diamidino-2-phenylindole (A-C, blue). Original magnification: 400x. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0221963) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-NBP2-24749-img0007.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP2-24749] - Representative immunofluorescence immunohistochemical-stained sections of colon adenocarcinoma metastasis to the liver showing the expression of KLF4 [red] on the cells within the tumor nests (TNs) [thin arrows] and those within the peritumoral stroma [arrowheads]. OCT4 [ green] was expressed on the KLF4+ [green, arrowheads] cells within the peritumoral stroma, and also cells within the peritumoral stroma that expressed KLF4 [ red, thick arrows] not expressing OCT4. c-Myc was expressed by cells within the TNs [green, arrows] and those within the peritumoral stroma [arrowheads]. The c-Myc+ population within the peritumoral stroma also expressed KLF4 [red]. Cell nuclei were counterstained with DAPI [blue]. Scale bars: 20 um. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fsurg.2017.00076/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP2-24749-img0008.jpg)
![Flow Cytometry: KLF4 Antibody [NBP2-24749] - Intracellular analysis using KLF4 antibody. Balb/c mouse splenocytes were probed using 1 ug of KLF4 antibody (red) and 1 ug of isotype control was used for this test, and an anti-rabbit IgG PE conjugated secondary .](http://images.novusbio.com/fullsize/KLF4-Antibody-Flow-Cytometry-NBP2-24749-img0003.jpg)
![Western Blot: KLF4 Antibody [NBP2-24749] - Lysate from human 293 cells in the (1) absence and (2) presence of immunizing peptide, (3) mouse NIH 3T3, and (4) RAW cells probed with KLF4 antibody at 1 ug/ml (293) and 2 ug/ml (NIH 3T3 and RAW). Goat anti-rabbit IgG HRP secondary and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/KLF4-Antibody-Western-Blot-NBP2-24749-img0001.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP2-24749] - Breast cancer tissues embedded in paraffin. Negative control is no primary antibody. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP2-24749-img0004.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP2-24749] - Representative 3,3-diaminobenzidine immunohistochemical stained images of WHO grade I meningioma for OCT4 (A, brown), NANOG (B, purple), SOX2 (C, brown), KLF4 (D, purple) & c-MYC (E, brown) expressed on the endothelial (red arrows) & pericyte (black arrows) layers. Cell nuclei were counterstained with hematoxylin (A-E, blue). Original magnification: 400X. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30417000), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24749_rabbit-polyclonal-klf4-antibody-310202415384146.jpg)
![Western Blot: KLF4 Antibody [NBP2-24749] - Representative Western blot images of total protein extracted from four head & neck metastatic malignant melanoma-derived primary cell lines probed for induced pluripotent stem cell markers. Blots were probed for OCT4 (A), NANOG (B), SOX2 (C), KLF4 (D), & c-MYC (E) & detected with HRP conjugated goat anti-rabbit antibody. alpha -Tubulin was used as the loading control (F) & detected using HRP conjugated mouse IgGĸ binding protein. Arrows indicate the presence of the proteins with their expected band sizes. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32019273), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24749_rabbit-polyclonal-klf4-antibody-310202415291941.jpg)
![Immunohistochemistry: KLF4 Antibody [NBP2-24749] - Representative immonoflourescence immunohistochemical stained images of WHO grade I meningioma demonstrating the expression of SOX2 (A, red), NANOG (B, red), KLF4 (C, red), OCT4 (D, green) & c-MYC (E, green) on both the SMA+ (A–C, red, red arrows) pericyte layer, & the ERG+ endothelial layer (D,E, red, white arrows). Cell nuclei were counterstained with 4′, 6′-diamino-2-phenylindole (A–F), blue. Original magnification: 600X. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30417000), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24749_rabbit-polyclonal-klf4-antibody-310202415392579.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP2-24749] - Representative colorimetric in situ hybridization stained images of WHO grade I meningioma demonstrating mRNA transcript expression for OCT4 (A, brown), NANOG (B, brown), SOX2 (C, brown), KLF4 (D, brown) & c-MYC (E, brown). Nuclei were counterstained with hematoxylin (A-E, blue). Orignal magnification: 1,000X. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30417000), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24749_rabbit-polyclonal-klf4-antibody-310202415371993.jpg)
![Immunocytochemistry/ Immunofluorescence: KLF4 Antibody [NBP2-24749] - Representative immunofluorescence immunohistochemical-stained sections of colon adenocarcinoma metastasis to the liver showing the expression of SOX2 [(A,D), red], NANOG [(B,E), red], KLF4 [(C,F), red], & c-Myc [(D–F), green] on the cells within the tumor nests (TNs) [(A–F), thin arrows] & those within the peritumoral stroma [(A–F), arrowheads]. OCT4 [(A–C), green] was expressed on the SOX2+ [(A), green, arrowheads], NANOG+ [(B), green, arrowheads], & KLF4+ [(C), green, arrowheads] cells within the peritumoral stroma. There were also cells within the peritumoral stroma that expressed SOX2 [(A), red, thick arrows], NANOG [(B), red, thick arrows] & KLF4 [(C), red, thick arrows] that did not express OCT4. c-Myc was expressed by cells within the TNs [(D–F), green, arrows] & those within the peritumoral stroma [(D–F), arrowheads]. The c-Myc+ population within the peritumoral stroma also expressed SOX2 [(D), red], NANOG [(E), red], & KLF4 [(F), red]. Cell nuclei were counterstained with 4′,6′-diamidino-2-phenylindole [(A–F), blue]. Scale bars: 20 µm. Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fsurg.2017.00076/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24749_rabbit-polyclonal-klf4-antibody-31020241613644.jpg)
![Immunocytochemistry/ Immunofluorescence: KLF4 Antibody [NBP2-24749] - Representative immunofluorescence immunohistochemical-stained sections of colon adenocarcinoma metastasis to the liver showing the expression of SOX2 [(A,D), red], NANOG [(B,E), red], KLF4 [(C,F), red], & c-Myc [(D–F), green] on the cells within the tumor nests (TNs) [(A–F), thin arrows] & those within the peritumoral stroma [(A–F), arrowheads]. OCT4 [(A–C), green] was expressed on the SOX2+ [(A), green, arrowheads], NANOG+ [(B), green, arrowheads], & KLF4+ [(C), green, arrowheads] cells within the peritumoral stroma. There were also cells within the peritumoral stroma that expressed SOX2 [(A), red, thick arrows], NANOG [(B), red, thick arrows] & KLF4 [(C), red, thick arrows] that did not express OCT4. c-Myc was expressed by cells within the TNs [(D–F), green, arrows] & those within the peritumoral stroma [(D–F), arrowheads]. The c-Myc+ population within the peritumoral stroma also expressed SOX2 [(D), red], NANOG [(E), red], & KLF4 [(F), red]. Cell nuclei were counterstained with 4′,6′-diamidino-2-phenylindole [(A–F), blue]. Scale bars: 20 µm. Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fsurg.2017.00076/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24749_rabbit-polyclonal-klf4-antibody-310202416114774.jpg)
![Immunohistochemistry-Paraffin: SMC1 Antibody [NB100-204] - FFPE section of mouse colon carcinoma CT26. Antibody: Affinity purified rabbit anti-SMC1 used at a dilution of 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/SMC1-Antibody-Immunohistochemistry-Paraffin-NB100-204-img0008.jpg "Immunohistochemistry-Paraffin: SMC1 Antibody [NB100-204] - FFPE section of mouse colon carcinoma CT26. Antibody: Affinity purified rabbit anti-SMC1 used at a dilution of 1:5,000 (0.2ug/ml). Detection: DAB")
![Immunohistochemistry-Paraffin: SMC1 Antibody [NB100-204] - FFPE section of human ovarian carcinoma. Antibody: Affinity purified rabbit anti-SMC1 used at a dilution of 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/SMC1-Antibody-Immunohistochemistry-Paraffin-NB100-204-img0007.jpg)
![Simple Western: SMC1 Antibody [NB100-204] - Simple Western lane view shows a specific band for SMC1 in 0.5 mg/ml of Hek293 (left) and HeLa (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SMC1-Antibody-Simple-Western-NB100-204-img0006.jpg)
![SMC1 Antibody [NB100-204] - Detection of human and mouse SMC1 by western blot. Samples: Whole cell lysate (50 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-SMC1 antibody NB100-204 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 seconds.Previous](http://images.novusbio.com/fullsize/SMC1-Antibody-NB100-204-img0009.jpg)
![SMC1 Antibody [NB100-204] - Detection of human SMC1 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-SMC1 antibody NB100-204 used for IP at 6 ug per reaction. SMC1 was also immunoprecipitated by rabbit anti-SMC1 recombinant monoclonal antibody NB2-76412. For blotting immunoprecipitated SMC1, NB100-204 was used at 1:1000. Detection: Chemiluminescence with an exposure time time of 10 seconds.](http://images.novusbio.com/fullsize/SMC1-Antibody-NB100-204-img0010.jpg)
![Western Blot: ATM Antibody (5C2) [NB100-220] - HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody (5C2) [NB100-220] diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced. Observed molecular weight ~320 kDa. Theoretical molecular weight 351 kDa.](http://images.novusbio.com/fullsize/ATM-Antibody-5C2-Western-Blot-NB100-220-img0007.jpg "Western Blot: ATM Antibody (5C2) [NB100-220] - HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody (5C2) [NB100-220] diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced. Observed molecular weight ~320 kDa. Theoretical molecular weight 351 kDa.")
![Immunocytochemistry/Immunofluorescence: ATM Antibody (5C2) [NB100-220] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: ATM protein stained by ATM antibody (5C2) [NB100-220] diluted at 1:200. Blue: Hoechst 33342 staining. Scale bar = 10 um.](http://images.novusbio.com/fullsize/ATM-Antibody-5C2-Immunocytochemistry-Immunofluorescence-NB100-220-img0004.jpg)
![Western Blot: ATM Antibody (5C2) [NB100-220] - Absence of Atm does not relieve the selective pressure to inactivate p53 during chemical carcinogenesis. Examples of cancer cell lines established from 3MC-fibrosarcomas (each line derives from an independent fibrosarcoma). The genotype of the mice where the 3MC-fibrosarcomas were generated is indicated, as well as, the status of p53 as determined by a nutlin-sensitivity assay (see Supplementary Figures S5 and S6). Cell lines were exposed to 10 Gy and protein extracts were obtained 1h and 24h after irradiation. The levels of the indicated proteins were determined by immunoblotting using beta-actin as loading control. Image collected and cropped by CiteAb from the following publication (www.dx.plos.org/10.1371/journal.pone.0005475) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ATM-Antibody-5C2-Western-Blot-NB100-220-img0008.jpg)
![Western Blot: ATM Antibody (5C2) [NB100-220] - Absence of Atm does not relieve the selective pressure to inactivate p53 during chemical carcinogenesis.A. Representative images of 3MC-fibrosarcomas immunostained for Arf, p53 & p21 (see also Table 1). The upper & middle rows are representative of the large majority of fibrosarcomas developed in wild-type (upper) & Atm-null (middle) mice, which are consistent with a mutant p53 (i.e. strongly positive for p53 & negative for p21). The lower row is representative of the fibrosarcomas developed in Arf-null mice, which are consistent with a functional p53 (i.e. very weakly positive for p53 & positive for p21). B. Examples of cancer cell lines established from 3MC-fibrosarcomas (each line derives from an independent fibrosarcoma). The genotype of the mice where the 3MC-fibrosarcomas were generated is indicated, as well as, the status of p53 as determined by a nutlin-sensitivity assay (see Supplementary Figures S5 & S6). Cell lines were exposed to 10 Gy & protein extracts were obtained 1h & 24h after irradiation. The levels of the indicated proteins were determined by immunoblotting using beta -actin as loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/19421407), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-31020241612655.jpg)
![Immunohistochemistry: ATM Antibody (5C2) [NB100-220] - Limited role of Atm in p53-mediated tumor suppression & DNA damage response in chemically-induced fibrosarcomas.A. Mice of the indicated genotypes, wt (n = 15), p53-super (n = 16), Atm-null (n = 9), p53-super/Atm-null (n = 13) & Arf-null (n = 12), were injected intramuscularly with 3-methyl-cholanthrene (3MC) & tumour development was monitored. Kaplan-Meier tumour-free curves were obtained & statistical significant differences (logrank test) were found for wt vs. p53-super (p<0.005), Atm-null vs. p53-super/Atm-null (p<0.001) & Arf-null vs. wt (p<0.0001). No significant differences were found for wt vs. Atm-null (p = 0.11), or p53-super vs. p53-super/Atm-null (p = 0.18). B. Quantification of the persistent DNA damage response ( gamma H2AX), proliferation (Ki67), & apoptosis (activated caspase-3) in 3MC-fibrosarcomas generated in mice of the indicated genotypes. Quantifications are relative to the 3MC-fibrosarcomas in wild-type mice. Values correspond to the average & standard deviation (n = 5 per genotype). Examples of the immunostainings are shown in the panels at the right. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/19421407), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-3102024165717.jpg)
![Immunocytochemistry/ Immunofluorescence: ATM Antibody (5C2) [NB100-220] - BAG3P209L aggregation leads to co-aggregation of proteasomal substrates. a Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT or FLAG-BAG3P209L using antibodies against BAG3 (green) or ubiquitin (red). Scale bar = 5 μm. b Suppression of GFP-HttQ74 aggregation of cells expressing a control, FLAG-BAG3WT or FLAG-BAG3P209L. Western blot against indicated antibodies is shown. c Quantification of GFP-HttQ74 aggregation of experiments similar to b. Relative percentage of SDS-insoluble protein levels are shown. Data represents the mean & standard deviation of three independent experiments. d Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT or FLAG-BAG3P209L using antibodies against BAG3 (green) or ubiquitin (red). Left column BAG3, middle column ubiquitin & right column is the merge of BAG3 (green), ubiquitin (red), & DAPI (blue). Scale bar = 5 μm. e Fractionation of HEK293 cells expressing HSPB8, a control or BAG3WT or BAG3P209L, together with either Ub-R-GFP or GFP-ODC (ornithine decarboxylase). Western blot against GFP, FLAG (BAG3), Myc (HSPB8), & tubulin are shown. f Fractionation of HEK293 cells expressing HSPB8 & indicated BAG3 variants. Western blot using ubiquitin (FK2) & tubulin antibodies are shown. The same samples as in Fig. 5e have been used, loading control is therefore the same. Source data are provided as a Source data file Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30559338), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-31020241553206.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0011.jpg "Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Staining of sections from a wild type mouse testis taken at P11 were probed with NB200-174 (green). Sections were stained with DAPI to reveal the position of cell nuclei (blue).](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Immunohistochemistry-NB200-174-img0008.jpg)
![Flow (Intracellular): p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - An intracellular stain was performed on HEK293 cells with p14ARF (5-C3-1) antibody NB200-174 (blue) and a matched isotype control MAB0061 (orange) [A]. An intracellular stain was also performed on THP-1 (known homozygous deletion of gene, PMID: 19635138) cells to ensure antibody specificity [B]. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Goat Anti-Rat F(ab)2 IgG (H+L) APC-conjugated Antibody (F0113, R&D Systems). *Note: This antibody recognizes both human (p14ARF) and mouse (p19ARF) versions of the protein.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Flow-Intracellular-NB200-174-img0010.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Aberrantly upregulated p19ARF/CDKN2A antagonizes TFH differentiation and survival. p19ARF/CDKN2A and Bcl6 interaction capacity. WT or mutant p19ARF/CDKN2A was co-transfected with WT Bcl6 expression vector into 293T cells. Cell lysates were immunoprecipitated with anti-Bcl6 and then immunoblotted with anti-p19ARF/CDKN2A. Data are representative of two experiments. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-07853-z) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0012.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Analysis of endogenous p19Arf. Total cell lysates (25 ug) from NIH3T3 cells, which have deleted the Arf gene (Lanes 1) and from wild type mouse embryo fibroblasts (MEFs) at passage 6, which express p19Arf (Lanes 2), were resolved by SDS-PAGE.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0005.jpg)
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Detection of p19Arf. Wild type mouse embryo fibroblasts (MEF) at passage 5 (panels 1, 2) and NIH3T3 cells, which have deleted the Arf gene (panels 3, 4) were probed with NB200-17 and nuclear stain (overlay in panels 2 and 4).](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Knockout-Validated-NB200-174-img0009.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Phosphorylation of NPM-Ser48 regulates the localization of NPM & p19A(A) Npm−/−, p53−/−double null MEF were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. Cells were fixed & stained with DAPI & anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates & whole cell lysates from Npm−/−;p53−/− MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed & stained with DAPI, anti-NPM & anti p19ARF. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-31020241621829.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416205122.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Loss of P19Arf enhances tumor growth & primary lung fibroblasts induce p19Arf in response to leucine deprivation (LD). (A) Graph of sarcoma (SKPY) tumor volume on the indicated days. SKPY cells were injected into the flank of WT & p19Arf-null mice. Tumor volume was measured by caliper. N=7 mice/WT cohort & N=15 mice/p19Arf−/− cohort. (B) Western blot for p19Arf protein expression in WT & Arf-null fibroblasts after LD for the indicated days. Densitometric quantification of p19Arf protein expression relative to beta -tubulin is shown on right. (C) qPCR for p19Arf mRNA in WT or p19Arf−/− fibroblasts during LD for the indicated days. (D) Representative immunofluorescence images for P19Arf subcellular localization on the indicated days after LD in WT or p19Arf−/− ALFs. Quantification of nuclear p19Arf is shown in graph on right. (E) Western blot analysis of phospho-eIF2 alpha (P-eIF2 alpha ) & total eIF2 alpha expression in WT & p19Arf-null murine ALFs during LD for the indicated days. Graph quantifies intensity of P-eIF2 alpha expression relative to day 0. beta -Tubulin used as loading control. (F) Western blot analysis of P-eIF2 alpha expression in WT & p19Arf−/− ALFs upon treatment with a GCN2 inhibitor (GCN2-IN-1; A-92 1 µM in DMSO) during overnight LD. Actin used as a loading control. Quantification of P-eIF2 alpha expression relative to total eIF2 alpha . N=3; *, P<0.05; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34994382), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416205128.jpg)
![Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Phosphorylation of NPM-Ser48 regulates the localization of NPM & p19A(A) Npm−/−, p53−/−double null MEF were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. Cells were fixed & stained with DAPI & anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates & whole cell lysates from Npm−/−;p53−/− MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed & stained with DAPI, anti-NPM & anti p19ARF. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416203717.jpg)
![Flow Cytometry: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free - Conducted the antibody trial with two different dilutions of p19ARF/CDKN2A Antibody (5-C3-1) [PE] (Catalog # NB200-174PE) (1:500 and 1:100) and compared them to an IgG control which was also PE labelled. Image from a verified customer review.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-312202414314910.png)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Human primary cells stained with Mre11 antibody at a dilution of 1:60. cells were fixed in 1:1 Acetone/Methanol. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunohistochemistry-NB100-473-img0008.jpg "Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Human primary cells stained with Mre11 antibody at a dilution of 1:60. cells were fixed in 1:1 Acetone/Methanol. ICC/IF image submitted by a verified customer review.")
![<b>Genetic Strategies Validation. </b>Western Blot: Mre11 Antibody (12D7) [NB100-473] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Mre11 antibody [12D7] diluted at 1:500. HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody. A band appears at the theoretical molecular weight of 80 kDa.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Western-Blot-NB100-473-img0010.jpg)
![Western Blot: Mre11 Antibody (12D7) [NB100-473] - Mre11 antibody [12D7] detects Mre11 protein by western blot analysis. A. 30 ug 293T whole cell extract. B. 30 ug whole cell extract of human Mre11-transfected 293T cells. 7.5% SDS-PAGE. Mre11 antibody [12D7] (NB100-473). HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody. Bands are prominent at the theoretical molecular weight of 80 kDa.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Western-Blot-NB100-473-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Analysis of Mre11 antibody (12D7) on lymphoblastoid cells. Dilution 1:200. Image from verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0021.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Mre11 antibody [12D7] detects Mre11 protein at nucleus by immunofluorescent analysis. Sample: HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Mre11 stained by Mre11 antibody [12D7] (NB100-473).Blue: Hoechst 33342 staining.Scale bar= 10 um.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (12D7) [NB100-473] - Mouse fibroblasts stained with Mre11 Antibody (12D7). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Mre11-Antibody-12D7-Immunocytochemistry-Immunofluorescence-NB100-473-img0020.jpg)
![Western Blot: Mre11 Antibody (12D7) [NB100-473] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Mre11 antibody [12D7] (NB100-473) diluted at 1:500. The HRP-conjugated anti-mouset IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nb100-473_mouse-monoclonal-mre11-antibody-12d7-91020242091437.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Simple Western: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Simple Western lane view shows a specific band for mtTFA in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Simple-Western-NBP1-71648-img0008.jpg "Simple Western: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Simple Western lane view shows a specific band for mtTFA in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Immunocytochemistry/Immunofluorescence: mtTFA Antibody (18G102B2E11) [NBP1-71648] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-mtTFA Antibody (18G102B2E11) NBP1-71648 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunocytochemistry-Immunofluorescence-NBP1-71648-img0014.jpg)
![Immunohistochemistry-Paraffin: mtTFA Antibody (18G102B2E11) [NBP1-71648] - IHC staining of mtTFA on human testis using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunohistochemistry-Paraffin-NBP1-71648-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: mtTFA Antibody (18G102B2E11) [NBP1-71648] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-mtTFA Antibody (18G102B2E11) NBP1-71648 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunocytochemistry-Immunofluorescence-NBP1-71648-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Immunostaining in HeLa cells. C1: DAPI staining 2 nuclei, C2: anti-mtTFA stain with Alexa Fluor 488 secondary ab (green), C3: Mitotracker Red staining mitochondria. Image courtesy of Elizabeth Wang.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunocytochemistry-Immunofluorescence-NBP1-71648-img0003.jpg)
![Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Total protein from Hela and U937 were separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-mtTFA NBP1-71648 in blocking buffer and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Western-Blot-NBP1-71648-img0017.jpg)
![Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Analysis of mtTFA expression in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Western-Blot-NBP1-71648-img0006.jpg)
![Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - MtDNA depletion & reversible impaired immune functions in THP-1 cells. A & B, Treatment with 50 ng/mL ethidium bromide (EtBr) for 8 weeks. A, MtDNA levels. B, LPS-induced TNF-alpha & IL-8 release. C-E, Transfection with 30 nmol/L negative or TFAM siRNA for 8 days. C, TFAM protein relative to beta -actin. D, MtDNA levels. E, LPS-induced TNF-alpha & IL-8 release. F-H, TFAM recovery 8 days after removal of TFAM siRNA. F, TFAM protein relative beta -actin. G, MtDNA levels. H, LPS-induced TNF-alpha & IL-8 release. All experiments are presented as means ± SD of 3 to 4 independent biological replicates. *P < .05, **P < .01, & ***P < .001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28629747), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-71648_mouse-monoclonal-mttfa-antibody-18g102b2e11-310202415384163.jpg)
![Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - MtDNA depletion & impaired immune functions & subsequent recovery in THP-1 cells following transfection with TFAM siRNA. A-G, Transfection with TFAM siRNA. A, TFAM proteins levels relative to beta -actin during titration of TFAM siRNA, showing optimal knockdown of TFAM protein after transfection of THP-1 cells with 30 nmol/L siRNA for 8 days. B, Cell viability. C, Cell proliferation. D, The levels of the MT-CO1 & SDHA proteins relative to beta -actin. D, OCR for different aspects of mitochondrial respiration & respiratory profile. E, Phagocytosis of E coli. Recovery 8 days after removal of TFAM siRNA. F, Levels of the MT-CO1 & SDHA proteins relative to beta -actin. G, Oxygen consumption for different aspects of mitochondrial respiration. H, Bacterial phagocytosis. All experiments were carried out on 3 to 4 independent biological replicates & are presented as means ± SD. **P < .01 & ***P < .001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28629747), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-71648_mouse-monoclonal-mttfa-antibody-18g102b2e11-310202416182618.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Staining of SIAH in human colorectal adenocarcinoma using NB110-88113. Staining of SIAH was not observed in normal colon epithelium. Photos courtesy of Dr. Amy Tang, Mayo Clinic Cancer Center.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunohistochemistry-NB110-88113-img0004.jpg "Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Staining of SIAH in human colorectal adenocarcinoma using NB110-88113. Staining of SIAH was not observed in normal colon epithelium. Photos courtesy of Dr. Amy Tang, Mayo Clinic Cancer Center.")
![Immunocytochemistry/Immunofluorescence: SIAH2 Antibody (24E6H3) [NB110-88113] - Staining of SIAH in ovarian carcinoma (OVCR3) cells using NB110-88113.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunocytochemistry-Immunofluorescence-NB110-88113-img0003.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Strong SIAH2 staining in all nuclei in this basal-like breast carcinoma. Image collected and cropped by CiteAb from the following publication (breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2828), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunohistochemistry-NB110-88113-img0006.jpg)
![Flow (Intracellular): SIAH2 Antibody (24E6H3) [NB110-88113] - Human HepG2 cell line was stained with Mouse Anti- SIAH2 Monoclonal Antibody (Catalog# NB110-88113, orange), or Mouse IgG1 isotype control (Catalog# MAB002, blue) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog# FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog# FC005).](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Flow-Intracellular-NB110-88113-img0005.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Moderate to strong staining of SIAH2 in the nucleus of a small proportion of the cell in a high nuclear grade ductal carcinoma in situ with comedo necrosis. Image collected and cropped by CiteAb from the following publication (breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2828), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunohistochemistry-NB110-88113-img0008.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Occasional weak to moderate SIAH2 (arrows) staining in a luminal type ductal carcinoma. Image collected and cropped by CiteAb from the following publication (breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2828), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunohistochemistry-NB110-88113-img0007.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Immunohistochemistry of candidate biomarkers in prostate cancer. Representative immunohistochemical staining of ACPP, ADAM9, ALDH1A2, CASR, CCND1, CCPG1, CD34, CD44, CD44v6, CHGA, CHMP1A, EI24, ENO2, GADD45B, HA, HAS2, HES6, HMMR, HOXC6, HYAL1, IGF1, IQCK, MAP4K4, MKI67, PAGE4, PLIN2, PTEN, SIAH2, SMAD4, SOX9, SPP1, SYP, & TP53 from prostate cancer tissue microarrays. Scale bar represents 50 μm. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-244), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-88113_mouse-monoclonal-siah2-antibody-24e6h3-310202415175276.jpg)
![Western Blot: Eg5 Antibody [NB500-181] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY KIF11 cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-Eg5.](http://images.novusbio.com/fullsize/Eg5-Antibody-Western-Blot-NB500-181-img0005.jpg "Western Blot: Eg5 Antibody [NB500-181] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY KIF11 cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-Eg5.")
![Immunocytochemistry/Immunofluorescence: Eg5 Antibody [NB500-181] - Staining of HeLa cells fixed in 3.5% paraformaldehyde. Cytoplasmic staining during interphase and spindle staining during mitosis.](http://images.novusbio.com/fullsize/Eg5-Antibody-Immunocytochemistry-Immunofluorescence-NB500-181-img0003.jpg)
![Western Blot: Eg5 Antibody [NB500-181] - Human Eg5 rescues depletion of the Drosophila kinesin-5 family member Klp61F. Western blot analysis of cell lysates prepared from induced and uninduced; control and Klp61F RNAi-treated cells blotted with anti-Eg5 to monitor induction of Eg5-mCherry, anti-Klp61F to confirm depletion of the motor and anti-alpha-tubulin as a loading control. Cells depleted of Klp61F and with Eg5-mCherry induced are referred to as RepEg5 cells. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fonc.2013.00187/abstract), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Eg5-Antibody-Western-Blot-NB500-181-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: Eg5 Antibody [NB500-181] - Spontaneous assembly of rosettes in iChM5 derivatives.Feeder free cultures iChM5Ap15 & iChM5Bp28 cells in chamber slides were immunostained as indicated. Left panel, emerging rosettes among self-renewing iPSCs; grayscale inset shows 1x magnification of immunostaining of Oct4 alone. Middle panel shows Nanog staining alone with inset at 2X magnification showing presumptive centrosomes (arrows). Bottom left panel shows forming rosettes immunopositive for Sox2 & Eg5. Bottom right panel shows low magnification image of immunostaining of Sox2 in this iChM5Ap15 culture, showing that virtually all cells were immunopositive. Grey scale inset shows representative forming rosette. Asterisks (*) in each panel indicates example of forming rosette. Scale bar, 50 microns. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25426336), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-181_rabbit-polyclonal-eg5-antibody-310202416171491.jpg)